MA-VERTEX-PHARMACEUTICAL
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022. Mr. Biller will report directly to Vertex’s Chief Executive Officer and President, Reshma Kewalramani, M.D., and join the company’s Executive Committee. In this role, Mr. Biller will oversee all of Vertex’s global legal and compliance functions.
“Jonathan is an outstanding addition to Vertex with his deep legal, industry and business experience, and I am delighted to welcome him to the company,” said Dr. Kewalramani. “Jonathan will lead an extraordinarily talented legal and compliance team and support our continued growth as we expand our leadership in cystic fibrosis, advance the pipeline across multiple diseases and modalities, and invest in the next wave of innovation.”
Mr. Biller joins Vertex from Agios, where he served in several executive roles including Chief Legal Officer and most recently Chief Financial Officer and Head of Corporate Affairs. Prior to this, he served as Executive Vice President, General Counsel at Celgene, where he was responsible for their global legal function, and before that as Senior Vice President, Tax and Treasury. Prior to Celgene, Mr. Biller was General Counsel, Chief Tax Officer and Secretary at Bunge Limited, a publicly traded agriculture and food company, and held roles of increasing responsibility at Alcon, Inc. during which time it was a publicly traded company. He began his legal career at Hopkins & Sutter rising to the level of partner and was also partner at Foley & Lardner after the firms merged. He holds a B.A. degree from Brown University and a J.D. from Yale Law School.
“Vertex has a highly differentiated strategy, a special culture that resonates with me, an impressive track record of success, and the potential to truly transform the treatment of multiple serious diseases. I am thrilled to have the opportunity to join the company at such an exciting time and work with such talented and committed colleagues to help build the company for the future,” said Mr. Biller.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 12 consecutive years on Science magazine's Top Employers list and one of the 2021 Seramount (formerly Working Mother Media) 100 Best Companies. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the second and fourth paragraphs of this press release. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, the risks listed under the heading “Risk Factors” in Vertex's most recent annual report filed with the Securities and Exchange Commission (SEC) and available through the company's website at www.vrtx.com and on the SEC’s website at www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.
(VRTX-GEN)
Source: Vertex Pharmaceuticals Incorporated
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005283/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 08:00:00 CEST | Press release
Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints
Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release
Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 07:00:00 CEST | Press release
Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%), HiSCR90 (13.8%-27.7%) and HiSCR100 (9.2%-21.3%) through Week 24Povorcitinib-treated patients also achieved greater improvements in skin pain by the first visit (Week 3) through Week 24 with 62%-70% achieving mild or no pain at Week 24 Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin17.9.2025 07:00:00 CEST | Press release
Results from a real-world clinical study conducted in China, to be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress, reveal that modern lifestyles and environmental triggers significantly impact individuals with sensitive skin1 Data show that people with sensitive skin living in modern environments have higher levels of inflammation compared to those living traditional, less stressful lifestyles1 This first-of-its-kind study was conducted by Galderma’s Global Sensitive Skincare Faculty (GSSF) as part of the company’s commitment to transforming the understanding and care of sensitive skin1 Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be pres
Ant International Recognized as an Inaugural Foreign Institution Partner by China’s Cross-Border Interconnection Payment Gateway17.9.2025 06:24:00 CEST | Press release
Expanded direct connection enables Alipay+ to help global wallets build China merchant networkAnt is the largest player in the CPG scheme in terms of coverage, use cases and business volume Ant International is appointed as an inaugural foreign Institution Partner (FIP) of China’s Cross-border Interconnection Payment Gateway (CPG), under the guidance of the People’s Bank of China and the Payment & Clearing Association of China (PCAC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916704996/en/ Eric Jing, Chairman of Ant Group and Ant International, and Cyril Han, CEO of Ant Group, celebrating China's Top International consumer destinations with card and wallet partners. Ant International and Alipay are the largest player in the CPG scheme with the largest number of card network and wallet partners, the broadest use cases and largest business volume. The new CPG scheme is designed to raise connection efficiency and improv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom